Neo Comprehensive™ - Solid Tumor
Precision Oncology: SIMPLER, BETTER, FASTER
Neo Comprehensive – Solid Tumor covers 517 cancer relevant genes with MSI/TMB using DNA and RNA to detect SNVs, Indels, CNVs, fusions and splice variants in a single NGS assay. Results delivered in 10 days.
RaDaR®: Personalizes detection of MRD
RaDaR delivers personalized detection of minimal residual disease (MRD) and recurrence, with a simple blood draw. RaDaR MRD testing is validated for use in multiple solid tumor cancers including breast, colorectal, lung and head & neck.
Neo Comprehensive™ - Myeloid Disorders
Neo Comprehensive Myeloid Disorders is a DNA & RNA next-generation sequencing (NGS) comprehensive genomic profile (CGP) analyzing 164 genes relevant in myeloid neoplasms for diagnostic evaluation, prognosis, risk stratification, and therapy guidance.
NeoTYPE® DNA & RNA – Lung
NeoTYPE® DNA & RNA – Lung is a targeted tissue-based assay featuring RNA-based fusion detection. Results delivered in only 10 days along with a simple, easy to interpret report.
Our specialty is cancer. Our mission is saving lives.
We create better, more hopeful futures for people living with cancer. It’s in our DNA.
As a leader in oncology testing, we endeavor to remove the complexities of diagnosing cancer and to empower oncologists, pathologists, and our pharma and biotech partners to provide patients with the best care possible. NeoGenomics enables precision oncology with the most advanced and comprehensive testing menu, ensuring you and your patients are equipped with the tools to optimize care.
All Patients, All Stages, All Clinical Needs
NeoGenomics partners with you and your cancer care team, leveraging our expertise to uncover the best treatment options for your personalized cancer care.